Literature DB >> 3263222

Qualitative study of fecal alpha 1-proteinase inhibitor in normal subjects and patients with Crohn's disease.

C Mizon1, C Becuwe, M Balduyck, J F Colombel, A Cortot, J Mizon, P Degand.   

Abstract

We applied sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting to analyze fecal alpha 1-proteinase inhibitor (alpha 1 PI) from healthy subjects and patients with Crohn's disease. A component with Mr 38,000 was characterized in normal fecal extracts as well as in six pathological samples. In these cases, the Crohn's disease activity index (CDAI), a clinical index of severity of the disease, was 170 (SEM 47). In contrast, alpha 1 PI of Mr 51,000 was detected in fecal extracts from eight patients with active Crohn's disease (CDAI = 287, SEM 39). We conclude that fecal alpha 1 PI can be considered a marker of intestinal disease activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3263222

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  3 in total

1.  Structural heterogeneity of faecal alpha 1 antitrypsin shown by immunoblot analysis in patients with Crohn's disease.

Authors:  F Boege; W Fischbach
Journal:  Gut       Date:  1991-05       Impact factor: 23.059

2.  Molecular form of faecal alpha 1 antitrypsin in patients with Crohn's disease.

Authors:  C Mizon; J eL Yamani; J Mizon; J F Colombel; A Cortot
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

3.  Qualitative differences in faecal alpha-1-antitrypsin in patients with Crohn's disease.

Authors:  J F Colombel; C Mizon; M Balduyck; A Cortot
Journal:  Gut       Date:  1989-02       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.